Crinetics Pharmaceuticals CRNX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $7.7M+641% | $1.04M-74.1% | $4.01M-15.3% | $4.74M+339% | ||
| —— | $0— | $0— | —— | ||
| —— | $1.04M-74.1% | $4.01M— | —— | ||
| $332.06M+38.3% | $240.16M+42.5% | $168.53M+29.4% | $130.23M+54.6% | ||
| $191.33M+91.8% | $99.74M+71.7% | $58.09M— | —— | ||
| —— | $99.74M+71.7% | $58.09M+37.0% | $42.39M+72.9% | ||
| —— | $339.89M+50.0% | $226.62M— | —— | ||
| -$516.77M-52.5% | -$338.85M-52.2% | -$222.61M-32.6% | -$167.88M-55.9% | ||
| -6,714.8%+25,899pp | -32,613.5%-27,066pp | -5,547.2%-2,003pp | -3,544.1%+6,447pp | ||
| $51.63M+26.2% | $40.92M+208% | $13.28M+167% | $4.97M+8,054% | ||
| $180K— | $0— | $0— | —— | ||
| -$465.32M-55.9% | -$298.41M-39.1% | -$214.53M-30.9% | -$163.92M-52.3% | ||
| -6,046.2%+22,674pp | -28,720.7%-23,375pp | -5,345.9%-1,885pp | -3,460.4%+6,525pp | ||
| -$4.94-33.5% | -$3.70-0.5% | -$3.68-16.8% | -$3.15-12.9% | ||
| -$512.88M-52.6% | -$336.07M-51.7% | -$221.51M-32.7% | -$166.9M-56.3% | ||
| -6,664.2%+25,681pp | -32,345.4%-26,826pp | -5,519.8%-1,997pp | -3,523.3%+6,382pp | ||
| -$516.77M-52.5% | -$338.85M-52.2% | -$222.61M-32.6% | -$167.88M-55.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Crinetics Pharmaceuticals's profit margins?
- Gross margin is 150.0% and operating margin is -3020.3%, with a -2747.2% net margin.
- Where does Crinetics Pharmaceuticals's income statement data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.